Related Experiment Video
Updated: Jul 9, 2026
![Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F55537.jpg&w=3840&q=50)
11:03
Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
Published on: May 29, 2017
10.1K
PEDRO: A Peer-to-Peer Support Platform for Adverse Drug Reaction Management in Patients with CLL
Christos Timamopoulos1, Thomas Chatzikonstantinou1, Panos Bonotis1
1Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Studies in Health Technology and Informatics
|July 1, 2025
Summary
Managing Chronic Lymphocytic Leukemia (CLL) involves risks of adverse drug reactions and interactions. The PEDRO platform enhances communication between healthcare professionals and experts to improve patient care and quality of life.
Area of Science:
- Oncology
- Pharmacology
- Health Informatics
Background:
- Chronic Lymphocytic Leukemia (CLL) treatment is associated with significant adverse drug reactions (ADRs) and drug-drug interactions (DDIs).
- These ADRs and DDIs negatively impact patients' quality of life (QoL).
- Effective management of these complications requires specialized knowledge and communication.
Purpose of the Study:
- To present the PEDRO platform, a novel solution designed to address challenges in managing ADRs and DDIs in CLL patients.
- To enhance peer-to-peer (P2P) communication and support among healthcare professionals (HCPs) involved in CLL patient care.
- To facilitate collaboration between frontline HCPs and CLL research experts.
Main Methods:
- Development of the PEDRO platform, a secure, scalable, and user-friendly system.
- Implementation of a P2P support model for ADR/DDI management.
- Focus on real-world healthcare settings for CLL patient management.
Main Results:
- The PEDRO platform provides a structured environment for HCPs to seek expert advice on ADRs/DDIs.
- Facilitates secure and efficient communication channels.
- Aims to improve the management of complex treatment-related issues in CLL.
Conclusions:
- The PEDRO platform offers a valuable tool for improving the management of ADRs and DDIs in Chronic Lymphocytic Leukemia.
- Enhances collaboration and knowledge sharing between healthcare professionals and experts.
- Contributes to improving patient outcomes and quality of life in CLL management.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...